Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
65.01
-0.10 (-0.15%)
Jun 27, 2025, 4:00 PM - Market closed
Hologic Revenue
Hologic had revenue of $1.01B in the quarter ending March 29, 2025, a decrease of -1.23%. This brings the company's revenue in the last twelve months to $4.03B, up 1.66% year-over-year. In the fiscal year ending September 28, 2024, Hologic had annual revenue of $4.03B, down -0.00%.
Revenue (ttm)
$4.03B
Revenue Growth
+1.66%
P/S Ratio
3.67
Revenue / Employee
$576,037
Employees
6,990
Market Cap
14.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 28, 2024 | 4.03B | -100.00K | -0.00% |
| Sep 30, 2023 | 4.03B | -832.40M | -17.12% |
| Sep 24, 2022 | 4.86B | -769.50M | -13.66% |
| Sep 25, 2021 | 5.63B | 1.86B | 49.14% |
| Sep 26, 2020 | 3.78B | 409.10M | 12.15% |
| Sep 28, 2019 | Pro | Pro | Pro |
| Sep 29, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 24, 2016 | Pro | Pro | Pro |
| Sep 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HOLX News
- 25 days ago - Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation - Business Wire
- 4 weeks ago - Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday? - Benzinga
- 4 weeks ago - Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports - Reuters
- 5 weeks ago - Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients - Business Wire
- 6 weeks ago - Hologic to Webcast Presentations at Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Hologic: Soft Performance, But Cheap Enough - Seeking Alpha
- 2 months ago - Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty - Reuters